RESEARCH TRIANGLE PARK, N.C., Oct. 22, 2016 /PRNewswire/ — Liquidia Technologies, Inc. today announced that the Company will present at the 6th Annual Partnership Opportunities in Drug Development (PODD) conference being held October 27–28, 2016 in Boston, MA. PODD is a strategic level program for pharma and biotech business development professionals that provides an overview of the latest developments in drug delivery technologies and opportunities to improve therapies.
Dr. Kevin Herlihy, Principal Scientist at Liquidia Technologies, will give a presentation titled Engineering Uniform Particles to Improve Drug Performancein which he will introduce the PRINT® technology for precisely engineering uniform drug particles to improve the performance of therapeutic medicines. He will highlight specific advantages to the controlled-release of small molecules and proteins.
Using its proprietary PRINT technology, Liquidia can optimize the performance of existing and novel therapeutics regardless of their size, route of administration or therapeutic indication. PRINT-optimized product candidates are in, or will soon enter, clinical development in pulmonary disease, post-operative pain management, and ophthalmology. In addition to advancing product candidates from its own pipeline, Liquidia actively partners with world-class collaborators, such as GlaxoSmithKline, to expand the applications for PRINT.
ABOUT LIQUIDIA TECHNOLOGIES
Liquidia Technologies is a biopharmaceutical company that has pioneered a simple, elegant solution to improve the performance of medicines by precisely engineering drug particles. Through its proprietary PRINT® technology, Liquidia has become the only company in the world that can improve the efficacy, safety, or route of administration, of nearly any therapeutic molecule by designing drug particles in a virtually unlimited number of compositions, sizes, or shapes. Leveraging aspects of biology and pharmaceutical chemistry with polymer science, PRINT technology represents an entirely novel approach to drug development and production, yet one that is also GMP capable, fully-scalable, and highly cost-effective. PRINT-optimized product candidates are in – or will soon enter – clinical development in pulmonary diseases, post-operative pain management and ophthalmology. In addition to advancing product candidates from its own pipeline, Liquidia actively partners with world-class collaborators, including GlaxoSmithKline, to expand the applications for PRINT technology.